Member Info for Kevinl1977

At these prices.
GLA

Wigster/doc
Many thanks for your excellent posting; it is much appreciated.
First class!
Lots of NOs from the Bod in the discussion, which is unsurprising.
‘the main point was that to attract/retain the calibre of people that Synairgen need to push forward and commercialise SNG001, they need salaries to be commensurate with industry standards/levels.’
Interesting and out of touch!
Many thanks, again.
My strategy is the same as Ghias.
Return at monthly/quarterly intervals to see what/if any progress has been made in this long journey.
ATB

Tommy
Of course it would be cheap to save a life, as I too stated.
Current SOC has been proven to save lives for a lot less than our drug costs.
Of course I hope I am very wrong and we suddenly get included on a platform trial, preferably in the US and that A2 data arrives and is excellent.
I’m just looking at the facts thus far, not hearsay or speculation.
Yes, I will be watching for the synopsis from Doc and wigster, etc.
ATB

Let’s face facts.
Who is going to use our product at £2k cost, unless it will save a life?
Any takers; I doubt it.
It is not cost friendly to treat flu or the common cold.
Usual response: we are having loads of discussion with potential ventures/trials.
What else can the BOD say?
We may find a market eventually for a certain sub group, but it’s way off at the moment.
No A2 data which I’m pretty sure is average, otherwise it would already be being investigated to prepare for the next variants or pandemic.
Let’s wait for another trial and then see what’s what.
GLA

Thanks doc for the brief feedback.
No need to know what’s happening on the Reddit board; apparently, in the place where the sun shines they already have the A2 data as they received it before the company did
The SP is just above where it was in Feb. Whatever rubbish is spouted or positivity shared the SP remains stagnant.
SP going nowhere until a TO happens.
University spin off that will not bring the drug to market, as they don’t have the capabilities to do so, imo.
Before you say it, yes I’m still invested for the long term but I certainly haven’t got my head in the sand like many on here, simply believing it will still happen.

Two very positive RNS’s and still the price stays the same.
Mmmm.

Whatever responses are given in the AGM, the SP on the day will no doubt plummet.
This is due to the lengthy timelines and investor patience that is required for the new trials to commence.
Unless, of course, there is a data driven RNS prior to the day or one which identifies acceptance onto a new trial.
ATB

Polar left a while ago, well documented.

Doc
100% agreed.

Manifesto
I hope you’re well.
This is an interesting topic, although we are nowhere near EUA yet; there will be no application until much stronger data is achieved from another trial.
Anyone thinking anything other is delusional.
GLA LTHs

Jun-22 16:13:46 127.875 410,000 Buy* 524.29k O
Rather large.

As with any business failure, someone or somebody needs to be held to account.
Who is it?

Everyone who has shares will get the opportunity to vote on this.
I completed this today, via my share dealer.
Couple of NO’s; I’m sure you can guess which ones.
GLA

Dac
I emailed her months ago about the same point.
No response.
Sharedealer - are you ever wrong?

OB
Glad it’s worked out well for your family.
Regarding using SNG to aid recovery, I can’t see how anyone would have the right to administer an unapproved drug to anyone unless they were part of a specific trial.
ATB

That’s good news potentially, Dave.
ATB

Operation Warpspeed; hardly!
Seamless link; hardly.
Next?

PAHOO
Relax.
ATB

SD
Yes, I know an awful lot about SNG but didn’t want to appear to be cross ramping another share on this board, as that isn’t my intention.
ATB.
Let’s hope this flies up

Too many people appear to be very emotionally connected to this share; beware as it bit me on the behind with Synairgen.
Until this drug is proven to work, not proven to in this board by people that don’t know including me, keep your feet on the ground and remain cautious but positive.
Everything lined up perfectly for SNG, including excellent data from P2, great feedback from the company and the advertisement of jobs over the pond that we’re going for help with commercialisation of the drug.
Unfortunately, none of those jobs came to fruition as the trial failed to meet its endpoints. This came as a major shock to investors and talk of £20-£50 a share now seems like a joke.
GLA and to myself as I am hoping to recoup some of my paper losses in this share.